Qure.ai has received U.S. Food and Drug Administration (FDA) clearance for qER-CTA, an algorithm designed to help analyze CT angiography scans for suspected large vessel occlusions (LVOs).
qER-CTA is trained to identify LVOs in the internal carotid artery and the M1 segment of the middle cerebral artery in adults, which can enable faster triage and specialist notification in emergency care scenarios, the company said. If left unidentified, LVOs can rapidly cause ischemic strokes. This is the 19th clearance for software that the company has received from the FDA, Qure.ai noted.
